Assessing risk of liver enzyme elevation in patients with immune-mediated diseases and different hepatitis B virus serostatus receiving anti-TNF agents: a nested case-control study

Table 3 Multivariate analysis of HBV infection status and liver enzyme elevation (Model 3)

Patient characteristics (n = 368)		OR (95% CI)
HBV infection status	HBsAg⁺ vs uninfected	7.91 (2.16–31.31)
HBV infection status	HBsAg^–/HBcAb⁺ vs uninfected	1.00 (0.33–3.25)
Sex	Female vs male	0.91 (0.34–2.54)
Age^a	20-year intervals	0.47 (0.24–0.91)
History of elevated ALT	History vs no history	13.71 (4.32–45.75)
Methotrexate	Methotrexate + folic acid vs no methotrexate	2.00 (0.61–7.20)
Methotrexate	Methotrexate alone without folic acid vs no methotrexate	11.60 (2.52–56.46)

^a Age categorised by 20-year intervals; 1 = 0–20 years, 2 = 20–40 years, 3 = 40–60 years, 4 = 60–80 years, 5 = ≥ 80 years
ALT alanine aminotransferase, CI confidence interval, HBcAb ⁺ HBV core antibody positive, HBsAg ⁺/^– HBV surface antigen positive/negative, HBV hepatitis B virus, OR odds ratio

ISSN: 1478-6362